COVID-19 vaccines offer protection against long-term effects, study suggests

Eliz­a­beth Mi­ly, the lead ac­qui­si­tion and deal ne­go­tia­tor at Bris­tol My­ers Squibb, is leav­ing the Big Phar­ma, a spokesper­son con­firmed to End­points News on Fri­day

As­traZeneca and Dai­ichi Sankyo’s multi­bil­lion-dol­lar an­ti­body-drug con­ju­gate al­liance has gen­er­at­ed a Phase III win, the part­ners say, beef­ing up the case that they have a